Literature DB >> 29190254

Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator.

Hunter B Moore1, Ernest E Moore, Benjamin R Huebner, Monika Dzieciatkowska, Gregory R Stettler, Geoffrey R Nunns, Peter J Lawson, Arsen Ghasabyan, James Chandler, Anirban Banerjee, Christopher Silliman, Angela Sauaia, Kirk C Hansen.   

Abstract

BACKGROUND: Fibrinolysis shutdown (SD) is an independent risk factor for increased mortality in trauma. High levels of plasminogen activator inhibitor-1 (PAI-1) directly binding tissue plasminogen activator (t-PA) is a proposed mechanism for SD; however, patients with low PAI-1 levels present to the hospital with a rapid TEG (r-TEG) LY30 suggestive SD. We therefore hypothesized that two distinct phenotypes of SD exist, one, which is driven by t-PA inhibition, whereas another is due to an inadequate t-PA release in response to injury.
METHODS: Trauma activations from our Level I center between 2014 and 2016 with blood collected within an hour of injury were analyzed with r-TEG and a modified TEG assay to quantify fibrinolysis sensitivity using exogenous t-PA (t-TEG). Using the existing r-TEG thresholds for SD (<0.9%), physiologic (LY30 0.9-2.9%), and hyperfibrinolysis (LY30 > 2.9%) patients were stratified into phenotypes. A t-TEG LY30 greater than 95th percentile of healthy volunteers (n = 140) was classified as t-PA hypersensitive and used to subdivide phenotypes. A nested cohort had t-PA and PAI-1 activity levels measured in addition to proteomic analysis of additional fibrinolytic regulators.
RESULTS: This study included 398 patients (median New Injury Severity Score, 18), t-PA-Sen was present in 27% of patients. Shutdown had the highest mortality rate (20%) followed by hyperfibinolysis (16%) and physiologic (9% p = 0.020). In the non-t-PA hypersensitive cohort, SD had a fivefold increase in mortality (15%) compared with non-SD patients (3%; p = 0.003) which remained significant after adjusting for Injury Severity Score and age (p = 0.033). Overall t-PA activity (p = 0.002), PAI-1 (p < 0.001), and t-PA/PAI-1 complex levels (p = 0.006) differed between the six phenotypes, and 54% of fibrinolytic regulator proteins analyzed (n = 19) were significantly different.
CONCLUSION: In conclusion, acute fibrinolysis SD is not caused by a single etiology, and is clearly associated with PAI-1 activity. The differential phenotypes require an ongoing investigation to identify the optimal resuscitation strategy for these patients. LEVEL OF EVIDENCE: Prognostic, level III.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29190254      PMCID: PMC5726780          DOI: 10.1097/TA.0000000000001718

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  32 in total

1.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

2.  Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo.

Authors:  Denise Huber; Elisabeth M Cramer; Jocelyne E Kaufmann; Paolo Meda; Jean-Marc Massé; Egbert K O Kruithof; Ulrich M Vischer
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Persistent Fibrinolysis Shutdown Is Associated with Increased Mortality in Severely Injured Trauma Patients.

Authors:  Jonathan P Meizoso; Charles A Karcutskie; Juliet J Ray; Nicholas Namias; Carl I Schulman; Kenneth G Proctor
Journal:  J Am Coll Surg       Date:  2016-12-23       Impact factor: 6.113

4.  Abnormalities in fibrinolysis at the time of admission are associated with deep vein thrombosis, mortality, and disability in a pediatric trauma population.

Authors:  Christine M Leeper; Matthew D Neal; Christine McKenna; Jason L Sperry; Barbara A Gaines
Journal:  J Trauma Acute Care Surg       Date:  2017-01       Impact factor: 3.313

5.  Plasminogen activator inhibitor (PAI-1) in plasma and platelets.

Authors:  N A Booth; A J Simpson; A Croll; B Bennett; I R MacGregor
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

6.  Acquired dysfunction due to the circulation of "exhausted" platelets.

Authors:  F I Pareti; A Capitanio; L Mannucci; C Ponticelli; P M Mannucci
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

7.  Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery.

Authors:  J A Páramo; J Rifón; R Llorens; J Casares; M J Paloma; E Rocha
Journal:  Haemostasis       Date:  1991

8.  Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients.

Authors:  Michael P Chapman; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Fabia Gamboni; James G Chandler; Sanchayita Mitra; Arsen Ghasabyan; Theresa L Chin; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  J Trauma Acute Care Surg       Date:  2016-01       Impact factor: 3.313

9.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Authors:  M Irem Baharoglu; Charlotte Cordonnier; Rustam Al-Shahi Salman; Koen de Gans; Maria M Koopman; Anneke Brand; Charles B Majoie; Ludo F Beenen; Henk A Marquering; Marinus Vermeulen; Paul J Nederkoorn; Rob J de Haan; Yvo B Roos
Journal:  Lancet       Date:  2016-05-10       Impact factor: 79.321

10.  The incidence and magnitude of fibrinolytic activation in trauma patients.

Authors:  I Raza; R Davenport; C Rourke; S Platton; J Manson; C Spoors; S Khan; H D De'Ath; S Allard; D P Hart; K J Pasi; B J Hunt; S Stanworth; P K MacCallum; K Brohi
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

View more
  25 in total

Review 1.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

2.  Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays.

Authors:  Gregory R Stettler; Ernest E Moore; Hunter B Moore; Geoffrey R Nunns; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-04       Impact factor: 3.313

3.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

4.  A clinical coagulopathy score concurrent with viscoelastic testing defines opportunities to improve hemostatic resuscitation and enhance blood product utilization during liver transplantation.

Authors:  Alexander C Schulick; Hunter B Moore; Carson B Walker; Hillary Yaffe; James J Pomposelli; Fareed Azam; Michael Wachs; Thomas Bak; Peter Kennealey; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Michael P Chapman; Elizabeth A Pomfret; Trevor L Nydam
Journal:  Am J Surg       Date:  2020-09-01       Impact factor: 2.565

Review 5.  Trauma-induced coagulopathy: The past, present, and future.

Authors:  Lucy Z Kornblith; Hunter B Moore; Mitchell J Cohen
Journal:  J Thromb Haemost       Date:  2019-05-13       Impact factor: 5.824

6.  It's sooner than you think: Blunt solid organ injury patients are already hypercoagulable upon hospital admission - Results of a bi-institutional, prospective study.

Authors:  Julia R Coleman; Annika B Kay; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Sarah Majercik; Mitchell J Cohen; Thomas White; Fredric M Pieracci
Journal:  Am J Surg       Date:  2019-09-10       Impact factor: 2.565

7.  Goal-directed hemostatic resuscitation for trauma induced coagulopathy: Maintaining homeostasis.

Authors:  Ernest E Moore; Hunter B Moore; Michael P Chapman; Eduardo Gonzalez; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

Review 8.  Alterations in platelet behavior after major trauma: adaptive or maladaptive?

Authors:  Paul Vulliamy; Lucy Z Kornblith; Matthew E Kutcher; Mitchell J Cohen; Karim Brohi; Matthew D Neal
Journal:  Platelets       Date:  2020-01-27       Impact factor: 3.862

9.  Precision Medicine: Clinical Tolerance to Hyperfibrinolysis Differs by Shock and Injury Severity.

Authors:  Navin G Vigneshwar; Ernest E Moore; Hunter B Moore; Bryan A Cotton; John B Holcomb; Mitchell J Cohen; Angela Sauaia
Journal:  Ann Surg       Date:  2022-03-01       Impact factor: 12.969

10.  28-day thawed plasma maintains α2 -antiplasmin levels and inhibits tPA-induced fibrinolysis.

Authors:  Gregory R Stettler; Ernest E Moore; Benjamin R Huebner; Geoffrey R Nunns; Hunter B Moore; Julia R Coleman; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman
Journal:  Vox Sang       Date:  2020-09-07       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.